Payment overview · 2025
General Payments
$256.82
9 reported records · 2 companies
Healthcare provider profile · identity verified
David A. Hurst, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PORT ST LUCIE, FL · NPI 1093975161
Verified facts
What the public records show
CMS Open Payments records show David A. Hurst, M.D. received $256.82 in general payments during 2025 across 9 reported records.
Novo Nordisk Inc accounted for 85.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $219.35 | 85.4% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.47 | 14.6% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $256.82 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $160.15 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.20 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.47 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $37.47 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 220 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
220 | 47 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
60 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 691 | 200 |
| Atorvastatin Calcium | Atorvastatin Calcium | 650 | 189 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 612 | 188 |
| Levothyroxine Sodium | Levothyroxine Sodium | 589 | 153 |
| Losartan Potassium | Losartan Potassium | 517 | 162 |
| Lisinopril | Lisinopril | 506 | 145 |
| Omeprazole | Omeprazole | 366 | 110 |
| Hydrochlorothiazide | Hydrochlorothiazide | 330 | 96 |
| Metformin Hcl | Metformin Hcl | 302 | 88 |
| Metoprolol Succinate | Metoprolol Succinate | 292 | 94 |
| Simvastatin | Simvastatin | 250 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 239 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 228 | 74 |
| Ozempic | Semaglutide | 220 | 47 |
| Gabapentin | Gabapentin | 200 | 65 |
| Trazodone Hcl | Trazodone Hcl | 199 | 62 |
| Tramadol Hcl | Tramadol Hcl | 195 | 38 |
| Sertraline Hcl | Sertraline Hcl | 182 | 55 |
| Allopurinol | Allopurinol | 170 | 46 |
| Lorazepam | Lorazepam | 166 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 159 | 59 |
| Eliquis | Apixaban | 152 | 38 |
| Jardiance | Empagliflozin | 146 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 126 | 35 |
| Valsartan | Valsartan | 125 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 33 |
| Montelukast Sodium | Montelukast Sodium | 114 | 30 |
| Clonazepam | Clonazepam | 113 | 25 |
| Alprazolam | Alprazolam | 111 | 27 |
| Ezetimibe | Ezetimibe | 110 | 32 |
| Glipizide | Glipizide | 110 | 35 |
| Meloxicam | Meloxicam | 108 | 46 |
| Metformin Hcl Er | Metformin Hcl | 101 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 96 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 92 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 26 |
| Atenolol | Atenolol | 83 | 27 |
| Celecoxib | Celecoxib | 75 | 29 |
| Potassium Chloride | Potassium Chloride | 75 | 28 |
| Carvedilol | Carvedilol | 74 | 21 |
| Furosemide | Furosemide | 68 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 19 |
| Diazepam | Diazepam | 62 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 18 |
| Rybelsus | Semaglutide | 60 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 18 |
| Famotidine | Famotidine | 56 | 17 |
| Finasteride | Finasteride | 56 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 16 |
| Synthroid | Levothyroxine Sodium | 52 | 14 |
| Glimepiride | Glimepiride | 51 | 14 |
| Glipizide Er | Glipizide | 50 | 17 |
| Sildenafil Citrate | Sildenafil Citrate | 50 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 15 |
| Benazepril Hcl | Benazepril Hcl | 46 | 13 |
| Alendronate Sodium | Alendronate Sodium | 44 | 17 |
| Methylprednisolone | Methylprednisolone | 43 | 37 |
| Pregabalin | Pregabalin | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 42 | 11 |
| Spironolactone | Spironolactone | 41 | 14 |
| Bupropion Xl | Bupropion Hcl | 40 | 13 |
| Lovastatin | Lovastatin | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | suppressed |
| Ramipril | Ramipril | 35 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | 12 |
| Azithromycin | Azithromycin | 34 | 31 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Irbesartan | Irbesartan | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 32 | 11 |
| Amoxicillin | Amoxicillin | 31 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 14 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | 11 |
| Valacyclovir | Valacyclovir Hcl | 23 | 11 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Prednisone | Prednisone | 20 | 17 |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 11 |
| Anastrozole | Anastrozole | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 15 |
| Diclofenac Potassium | Diclofenac Potassium | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Zaleplon | Zaleplon | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Telmisartan | Telmisartan | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Diclofenac Sodium Er | Diclofenac Sodium | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $256.82 · 9 records | Novo Nordisk Inc | OTEZLA, Ozempic, REPATHA, Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error